NCT07116746View on ClinicalTrials.gov

Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

January 31, 2027

Conditions
GoutGouty ArthritisHyperuricemiaGout ChronicRefractory GoutUncontrolled GoutTophaceous Gout
Interventions
DRUG

AR882 75 mg

Solid Oral Capsule

DRUG

XOI Low Dose

Solid Oral Tablet

DRUG

XOI High Dose

Solid Oral Tablet

Sponsors
All Listed Sponsors
lead

Arthrosi Therapeutics

INDUSTRY

NCT07116746 - Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients | Biotech Hunter | Biotech Hunter